<?xml version="1.0" encoding="UTF-8" standalone="yes"?><Trial id="248590"><TitleDisplay>Vedolizumab IV 300 mg in the Treatment of Fistulizing Crohn's Disease</TitleDisplay><TitleOfficial>A Randomized, Double-Blind, Phase IV Study to Evaluate the Safety and Proportion of Subjects With Fistula Healing in Two Dose Regimens of Entyvio (Vedolizumab IV) in the Treatment of Fistulizing Crohn's Disease (ENTERPRISE)</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02630966</Identifier><Identifier type="Secondary Organisational">2015-000852-12</Identifier><Identifier type="Secondary Organisational">U1111-1174-2252</Identifier><Identifier type="Organisational Study">VEDOLIZUMAB-4003</Identifier><Identifier type="Trial Acronym">ENTERPRISE</Identifier></Identifiers><Indications><Indication id="3054">Fistula</Indication><Indication id="84">Crohns disease</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>vedolizumab</Name><Drug id="12406">vedolizumab</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="12406">vedolizumab</Drug><IndicationsPioneer><Indication id="3054">Fistula</Indication></IndicationsPioneer><Companies><Company><Company id="1052214">Takeda Development Centre Europe Ltd</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>CURRENT</RelationshipInDirect></Company><Company><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>FORMER</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="12406" type="Drug"><TargetEntity id="257898" type="siDrug">Vedolizumab</TargetEntity></SourceEntity><SourceEntity id="1052214" type="Company"><TargetEntity id="5001199852" type="organizationId">Takeda Pharmaceuticals Europe Ltd</TargetEntity></SourceEntity><SourceEntity id="20300" type="Company"><TargetEntity id="4295877353" type="organizationId">Takeda Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="3054" type="ciIndication"><TargetEntity id="10016717" type="MEDDRA"/><TargetEntity id="D005402" type="MeSH"/><TargetEntity id="-1818387917" type="omicsDisease"/><TargetEntity id="3342" type="siCondition"/></SourceEntity><SourceEntity id="84" type="ciIndication"><TargetEntity id="K50" type="ICD10"/><TargetEntity id="10011401" type="MEDDRA"/><TargetEntity id="D003424" type="MeSH"/><TargetEntity id="-248155260" type="omicsDisease"/><TargetEntity id="395" type="siCondition"/></SourceEntity><SourceEntity id="2617" type="Action"><TargetEntity id="3663" type="Mechanism">Integrin alpha4beta7 (MAdCAM) Antagonists</TargetEntity></SourceEntity><SourceEntity id="2950" type="Action"><TargetEntity id="1032" type="Mechanism">Integrin alpha4beta7 (LPAM-1) Antagonists</TargetEntity><TargetEntity id="3669" type="Mechanism">Anti-alpha4beta7</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 4 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>21</NumberOfSites><CompaniesSponsor><Company id="1052214">Takeda Development Centre Europe Ltd</Company><Company id="20300">Takeda Pharmaceutical Co Ltd</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="2617">MAdCAM inhibitor</Action><Action id="2950">Integrin alpha-4/beta-7 antagonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1332">Gastrointestinal system agent</Class><Class id="1594">Antibacterial</Class><Class id="2953">Anti-inflammatory</Class><Class id="396">Immunosuppressant</Class><Class id="55685">Anticancer monoclonal antibody</Class><Class id="991">Antiviral</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="898">Formulation powder</Technology><Technology id="750">Freeze drying</Technology><Technology id="573">Immunoglobulin-G</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="169">Monoclonal antibody humanized</Technology><Technology id="647">Subcutaneous formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>34</PatientCountEnrollment><DateStart>2016-08-10T00:00:00Z</DateStart><DateEnd type="actual">2018-11-14T00:00:00Z</DateEnd><DateChangeLast>2019-05-17T10:46:13Z</DateChangeLast><DateAdded>2015-12-21T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Takeda Development Centre Europe, Ltd.</Affiliation><Email>clinicaloperations@tgrd.com</Email><Name>Study Manager</Name><Phone>+4420 3116 8000</Phone></Contact><Contact type="Scientific contact"><Affiliation>Takeda</Affiliation><Name>Medical Director Clinical Science</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Adult subjects, aged 18 to 80 years, inclusive, with moderately to severely active CD and 1 to 3 draining perianal fistula(e) of at least 2 weeks duration&lt;/li&gt;&lt;li&gt;In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements&lt;/li&gt;&lt;li&gt;The participant or, when applicable, the participant's legally acceptable representative has signed and dated a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures&lt;/li&gt;&lt;li&gt;Has a diagnosis of CD established at least 3 months prior to randomization by clinical and endoscopic evidence and corroborated by a histopathology report&lt;/li&gt;&lt;li&gt;Has a diagnosis of a minimum of 1 perianal draining fistula of at least 2 weeks duration as a complication of moderately to severely active CD, as identified on magnetic resonance image (MRI) at screening. Other types of fistulae (enterocutaneous, abdominal) except rectovaginal fistulae are permitted, but the number of perianal draining fistulae is limited to 3&lt;/li&gt;&lt;li&gt;All countries except France: the participant, historically, had an inadequate response with, lost response to or was intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNF-alpha) antagonist for their underlying CD (does not require treatment failure for currently active draining fistula). France only: the participant, historically, failed (ie, had an inadequate response with, lost response to or was intolerant to) infliximab for treatment of their underlying CD or fistulizing CD&lt;/li&gt;&lt;li&gt;If the participant had noncutting perianal seton placement as part of standard care, seton must be removed by week 14 of the study&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Has a diagnosis of ulcerative colitis or indeterminate colitis&lt;/li&gt;&lt;li&gt;Has a perianal abscess &gt; cm or an abscess that the investigator feels requires drainage based on either clinical assessment or MRI&lt;/li&gt;&lt;li&gt;Has a Crohn's Disease Activity Index (CDAI) score &gt; 400&lt;/li&gt;&lt;li&gt;Has an ileostomy, colostomy or known fixed symptomatic stenosis of the intestine&lt;/li&gt;&lt;li&gt;Has significant anal or rectal stenosis&lt;/li&gt;&lt;li&gt;Has active or latent tuberculosis (TB), regardless of treatment history&lt;/li&gt;&lt;li&gt;Has evidence of active Clostridium difficile (C. difficile) infection or is having treatment for C. difficile infection or other intestinal pathogens during Screening&lt;/li&gt;&lt;li&gt;Has current rectovaginal fistula&lt;/li&gt;&lt;li&gt;Currently has more than three draining perianal fistulae&lt;/li&gt;&lt;li&gt;Subjects who have a positive progressive multifocal leukoencephalopathy (PML) subjective checklist&lt;/li&gt;&lt;li&gt;Subjects who have received any investigational or approved biologic or biosimilar agent within 60 days of randomization&lt;/li&gt;&lt;li&gt;Subjects who have had prior exposure to vedolizumab, natalizumab, efalizumab, or rituximab, etrolizumab, or anti- mucosal addressin cell adhesion molecule-1 (MAdCAM-1) therapy&lt;/li&gt;&lt;li&gt;Subjects who have a known history of hepatitis B virus (HBV), hepatitisC virus (HCV), acquired human immunodeficiency virus (HIV), or arefound to be seropositive at screening&lt;ul&gt;&lt;li&gt;Note: other protocol-defined inclusion/exclusion criteria may apply&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Subjects who have any evidence of an active infection (eg, sepsis, cytomegalovirus, or listeriosis) during screening, other than related to the fistula(e)&lt;/li&gt;&lt;li&gt;Subjects who have received any investigational or approved biologic or biosimilar agent within 60 days or 5 half-lives of randomization (whichever is longer)&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Percentage of participants with a reduction of at least 50% in the number of draining perianal fistula: closed fistula are no longer draining despite gentle finger compression</Description><Timeframe>Day 1, week 30</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Duration of perianal fistula response: duration of fistula response will be measured by number of days with/without drainage</Description><Timeframe>Up to week 30</Timeframe></Measure><Measure><Description>Percentage of participants with 100% perianal fistula closure: closed fistula are no longer draining despite gentle finger compression</Description><Timeframe>Week 30</Timeframe></Measure><Measure><Description>Time to first perianal fistula closure: closed fistula are no longer draining despite gentle finger compression</Description><Timeframe>Up to week 30</Timeframe></Measure><Measure><Description>Time to last (100%) perianal fistula closure: closed fistula are no longer draining despite gentle finger compression</Description><Timeframe>Up to week 30</Timeframe></Measure><Measure><Description>Percentage of participants with a reduction of at least 50% from day 1 in the number of Draining Perianal Fistulae at weeks 22 and 30: closed fistulae are no longer draining despite gentle finger compression</Description><Timeframe>Weeks 22 and 30</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was to evaluate fistula healing at week 30 in two different dose      regimens of vedolizumab (&lt;ulink linkType="Drug" linkID="12406"&gt;Entyvio&lt;/ulink&gt;) iv 300 mg in patients with fistulizing Crohn's disease (CD).&lt;br/&gt;The secondary objective was to evaluate fistula healing over a 30-weeks evaluation period.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;This was a randomized,  double-blind, phase IV, dose-response and parallel-assignment study.&lt;/para&gt;&lt;para&gt;The drug vedolizumab      intravenous would be tested to treat  patients who have fistulizing Crohns disease (CD). This study      would look at fistula healing in patients who take vedolizumab intravenous. The study would enroll approximately 100 patients. &lt;/para&gt;&lt;para&gt;Patients would be randomly assigned (by      chance, like flipping a coin) to one of the two treatment groups which would remain      undisclosed to the patient and study doctor during the study (unless there is an urgent      medical need):&lt;br/&gt;Group 1: patients would receive 300 mg of vedolizumab iv at weeks 0, 2, 6, 14 and 22 and a placebo infusion           at week 10.&lt;br/&gt;Group 2: patients would receive 300 mg of vedolizumab iv at weeks 0, 2, 6, 10, 14 and 22.&lt;/para&gt;&lt;para&gt;This multicenter trial would be conducted worldwide. The overall time to participate in this      study from screening to 18 weeks after the last dose is 44 weeks. Patients  would make      multiple visits to the clinic, and would be contacted by telephone 6 months after last dose      of study drug for a follow-up assessment.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Belgium"><Sites><Site><RecruitmentStatus id="6">Terminated</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Study Manager</Name></Contact></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Canada"><Sites><Site><Name>GIRI (GI Research Institute)</Name><Address1>Vancouver</Address1><Address2>British Columbia</Address2><Address3>V6Z 2K5</Address3><CountrySubDivision>British Columbia</CountrySubDivision><Contacts/></Site><Site><Name>University of Calgary</Name><Address1>Calgary</Address1><Address2>Alberta</Address2><Address3>T2N 4Z6</Address3><CountrySubDivision>Alberta</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Spain"><Sites><Site><Name>Hospital Clinic Barcelona</Name><Address1>Barcelona</Address1><Address3>08036</Address3><Contacts/></Site><Site><Name>Hospital Universitario y Politecnico La Fe</Name><Address1>Valencia</Address1><Address3>46026</Address3><Contacts/></Site><Site><RecruitmentStatus id="4">Completed</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Study Manager</Name></Contact></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="France"><Sites><Site><Name>CHRU de Lille - Hopital Claude Huriez</Name><Address1>Lille cedex</Address1><Address3>59037</Address3><Contacts/></Site><Site><Name>CHU de Rennes - Hopital de Pontchaillou</Name><Address1>Rennes cedex 9</Address1><Address3>35033</Address3><Contacts/></Site><Site><Name>Hopital de Brabois</Name><Address1>Vandoeuvre les Nancy</Address1><Address3>54511</Address3><Contacts/></Site><Site><Name>Hopital l'Archet II</Name><Address1>Nice Cedex 3</Address1><Address3>06202</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="UK"><Sites><Site><Name>John Radcliffe Hospital</Name><Address1>Oxford</Address1><Address3>OX3 9DU</Address3><Contacts/></Site><Site><Name>Nottingham University Hospitals NHS Trust</Name><Address1>Nottingham</Address1><Address3>NG7 2UH</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Italy"><Sites><Site><Name>Azienda Ospedaliera S. Orsola-Malpighi</Name><Address1>Bologna</Address1><Address3>40138</Address3><Contacts/></Site><Site><Name>Istituto Clinico Humanitas IRCCS</Name><Address1>Milan</Address1><Address3>20089</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Netherlands"><Sites><Site><Name>Academic Medical Center</Name><Address1>Amsterdam</Address1><Address3>1105 AZ</Address3><Contacts/></Site><Site><Name>Erasmus MC</Name><Address1>Rotterdam</Address1><Address3>3015 CE</Address3><Contacts/></Site><Site><Name>Leids Universitair Medisch Centrum</Name><Address1>Leiden</Address1><Address3>2333 ZA</Address3><Contacts/></Site><Site><RecruitmentStatus id="4">Completed</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Study Manager</Name></Contact></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="US"><Sites><Site><Name>Texas Digestive Disease Consultants</Name><Address1>Southlake</Address1><Address2>Texas</Address2><Address3>76092</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts/></Site><Site><Name>Vanderbilt University Medical Center</Name><Address1>Nashville</Address1><Address2>Tennessee</Address2><Address3>37212-1375</Address3><CountrySubDivision code="TN">Tennessee</CountrySubDivision><Contacts/></Site><Site><Name>Virginia Mason Medical Center</Name><Address1>Seattle</Address1><Address2>Washington</Address2><Address3>98101</Address3><CountrySubDivision code="WA">Washington</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Crohns disease</Disease><PatientSegments><PatientSegment><PatientSegment id="3404">Subjects with Active Crohns Disease</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3406">Crohns Disease Subjects with Specific Disease Patterns</PatientSegment><SubSegments><SubSegment id="3407">Penetrating/fistulising crohns disease</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="3426">Subjects with Treatment Resistant Disease</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3754">Subjects with Moderate to Severe Crohns Disease</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02630966</Identifier></Identifiers></Registry><Registry><Name id="1001">European Clinical Trials Database (EudraCT)</Name><Identifiers><Identifier type="Secondary Organisational">2015-000852-12</Identifier></Identifiers></Registry><Registry><Name id="1004">WHO ICTRP</Name><Identifiers><Identifier type="Secondary Organisational">U1111-1174-2252</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Crohns disease" id="6309"><Endpoint>Assessment of Clinical Response</Endpoint><SubEndpoints><SubEndpoint disease="Crohns disease" id="6327">Patients achieving partial response (at least 50% reduction in draining fistulae)</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Crohns disease" id="6309"><Endpoint>Assessment of Clinical Response</Endpoint><SubEndpoints><SubEndpoint disease="Crohns disease" id="6324">Maintenance of fistula closure</SubEndpoint><SubEndpoint disease="Crohns disease" id="6325">Clinical assessment of drainage</SubEndpoint><SubEndpoint disease="Crohns disease" id="6326">Patients achieving complete response (closure of all fistulae)</SubEndpoint><SubEndpoint disease="Crohns disease" id="6330">Time to fistula closure</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Crohns disease" id="6471"><Endpoint>Protocol Specified Other Endpoints</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Crohns disease" id="6406"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></OtherEndpoint><OtherEndpoint disease="Crohns disease" id="6439"><Endpoint>Assessment of Safety and Tolerability</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Crohns disease" id="3162"><Criterion>Subjects with Active Crohn's Disease</Criterion></Inclusion><Inclusion disease="Crohns disease" id="3168"><Criterion>Subjects with Specific Disease Patterns Based on the Primary Behavior</Criterion><SubCriteria><SubCriterion disease="Crohns disease" id="3170">Penetrating/fistulising crohn's disease</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Crohns disease" id="3204"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Crohns disease" id="3205">Subjects with history of/scheduled to receive antibiotics</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Crohns disease" id="3215"><Criterion>Subjects with Treatment Resistant Disease</Criterion></Inclusion><Inclusion disease="Crohns disease" id="3248"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Crohns disease" id="3250">Subjects undergone /willing to undergo study procedures</SubCriterion><SubCriterion disease="Crohns disease" id="3278">Subject acceptability/compliance</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Crohns disease" id="3273"><Criterion>Subjects with Hypersensitivity/Intolerance to Therapy</Criterion></Inclusion><Inclusion disease="Crohns disease" id="4345"><Criterion>Subjects with Moderate to Severe Crohn's Disease</Criterion></Inclusion><Inclusion disease="Crohns disease" id="34139"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Crohns disease" id="3253">Women with adequate contraception/Negative pregnancy test/Non-lactating women</SubCriterion><SubCriterion disease="Crohns disease" id="3255">Men with adequate contraception</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Crohns disease" id="34351"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Crohns disease" id="3249">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Crohns disease" id="4365"><Criterion>Crohn's Disease with Complications</Criterion><SubCriteria><SubCriterion disease="Crohns disease" id="4369">Subjects with sepsis as a disease complication</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Crohns disease" id="4381"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion><SubCriteria><SubCriterion disease="Crohns disease" id="4384">colostomy/ileostomy </SubCriterion></SubCriteria></Exclusion><Exclusion disease="Crohns disease" id="4388"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Crohns disease" id="4395">Subjects with neurologic/psychiatric disorders</SubCriterion><SubCriterion disease="Crohns disease" id="4396">Subjects co-morbid with hematological disease/disorders</SubCriterion><SubCriterion disease="Crohns disease" id="4398">Subjects co-morbid with metabolic diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Crohns disease" id="4389"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Crohns disease" id="4393"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Crohns disease" id="4403"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion><SubCriteria><SubCriterion disease="Crohns disease" id="4405">Subjects co-morbid with Ulcerative colitis</SubCriterion><SubCriterion disease="Crohns disease" id="4406">Subjects with indeterminate colitis</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Crohns disease" id="4407"><Criterion>Subjects co-morbid with infections</Criterion><SubCriteria><SubCriterion disease="Crohns disease" id="4397">Subjects co-morbid with HIV infection</SubCriterion><SubCriterion disease="Crohns disease" id="4415">Subjects co-morbid with Listeria infection</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Crohns disease" id="4418"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Crohns disease" id="4423"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion><SubCriteria><SubCriterion disease="Crohns disease" id="4425">Abnormal hematological findings</SubCriterion><SubCriterion disease="Crohns disease" id="4426">Abnormal liver function test</SubCriterion><SubCriterion disease="Crohns disease" id="4427">Subjects with abnormal renal function tests</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Crohns disease" id="4453"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion><SubCriteria><SubCriterion disease="Crohns disease" id="4504">Vaccination</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Crohns disease" id="4455"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Crohns disease" id="4458">Subjects unsuitable for study participation as per investigator's assessment</SubCriterion><SubCriterion disease="Crohns disease" id="4464">Subjects with history of/scheduled to receive an investigational drug</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Crohns disease" id="25742"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Crohns disease" id="4460">Pregnant/lactating women</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Crohns disease" id="25787"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Crohns disease" id="4432">Hypersensitivity/Contraindications to study medications or its excipients</SubCriterion><SubCriterion disease="Crohns disease" id="4433">Hypersensitivity/Contraindications to antibiotics</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Crohns disease" id="26081"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion><SubCriteria><SubCriterion disease="Crohns disease" id="4390">Subjects co-morbid with hepatic diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Crohns disease" id="28261"><Criterion>Subjects co-morbid with Hepatic Disorders/Diseases</Criterion><SubCriteria><SubCriterion disease="Crohns disease" id="4410">Subjects co-morbid with hepatitis</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Crohns disease" id="29237"><Criterion>Subjects with history of psychiatric disease/disorder</Criterion><SubCriteria><SubCriterion disease="Crohns disease" id="4465">Subjects with history of drug/substance abuse</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2018-09-04T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2018-06-30T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>22.71 Months</EnrollmentPeriod><EnrollmentRate>1.50 Patients/Month</EnrollmentRate><DateFirstReceived>2015-12-11T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2015-12-21T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2016-07-29T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2018-06-20T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2019-02-06T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="updated"><Date>2019-02-06T00:00:00Z</Date><Reason id="315">Eligibility Criteria updates</Reason></Change><Change type="updated"><Date>2019-03-20T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="updated"><Date>2019-03-20T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="updated"><Date>2019-03-20T00:00:00Z</Date><Reason id="315">Eligibility Criteria updates</Reason></Change><Change type="updated"><Date>2019-03-20T00:00:00Z</Date><Reason id="315">Eligibility Criteria updates</Reason></Change></ChangeHistory></Trial>